Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting

被引:1
|
作者
Mannelli, Paolo [1 ]
Douaihy, Antoine B. [2 ]
Akerman, Sarah C. [3 ]
Legedza, Anna [3 ]
Fratantonio, James [3 ]
Zavod, Abigail [3 ]
Sullivan, Maria A. [3 ,4 ]
机构
[1] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, 3074,2213 Elba St,Ste 156, Durham, NC 27705 USA
[2] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA
[3] Alkermes Inc, Waltham, MA USA
[4] Columbia Univ, Dept Psychiat, New York, NY USA
来源
AMERICAN JOURNAL ON ADDICTIONS | 2022年 / 31卷 / 02期
关键词
D O I
10.1111/ajad.13264
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background and Objectives Treatment for individuals receiving medication for opioid use disorder (MOUD) should follow an informed patient-centered approach. To better support patient autonomy in the decision-making process, clinicians should be aware of patient preferences and be prepared to educate and assist patients in transitioning from one MOUD to another, when clinically indicated. This posthoc analysis describes the characteristics of clinical trial participants (NCT02696434) with a history of opioid use disorder (OUD) seeking to transition from buprenorphine (BUP) to extended-release naltrexone (XR-NTX). Methods The posthoc analysis included adults with OUD currently receiving BUP (<= 8 mg/day) and seeking transition to XR-NTX (N = 101) in a residential setting. Baseline participant characteristics and OUD treatment history were reviewed. All patients completed a screening questionnaire that asked about their reasons for seeking transition to XR-NTX and for choosing BUP. Results The most common reasons for initiating a transition to XR-NTX were "Seeking to be opioid-free" (63.4%) and "Tired of daily pill taking" (25.7%). Positive predictors of transition included a more extensive BUP treatment history and a history of prescription opioid abuse. Most participants stated they were not aware of XR-NTX as a treatment option when initiating BUP (78.2%). Discussions and Conclusions Patients' reasons for seeking XR-NTX transition, more extensive BUP treatment history, and a history of prescription opioid abuse, may positively predict outcomes. Scientific Significance These findings may assist clinicians in optimizing outcomes of the BUP to XR-NTX transition and supporting patients to make better informed MOUD decisions.
引用
收藏
页码:142 / 147
页数:6
相关论文
共 50 条
  • [41] Pain Management in Patients With Opioid Use Disorder on Extended-release Buprenorphine: A Case Report
    South, Anna-Maria
    Oller, Devin
    Lofwall, Michelle
    Fanucchi, Laura C.
    JOURNAL OF ADDICTION MEDICINE, 2024, 18 (01) : 86 - 89
  • [42] EXTENDED-RELEASE NALTREXONE VERSUS ORAL NALTREXONE FOR ALCOHOL USE DISORDER TREATMENT IN PRIMARY CARE
    Chen, J.
    Obi, R.
    Wong, S.
    Flannery, M.
    McDonald, R.
    Tofighi, B.
    Kermack, A.
    Laska, E.
    Rotrosen, J.
    Gourevitch, M. N.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2016, 40 : 233A - 233A
  • [43] Extended-release naltrexone opioid treatment at jail reentry (XOR)
    McDonald, Ryan D.
    Tofighi, Babak
    Laska, Eugene
    Goldfeld, Keith
    Bonilla, Wanda
    Flannery, Mara
    Santana-Correa, Nadina
    Johnson, Christopher W.
    Leibowitz, Neil
    Rotrosen, John
    Gourevitch, Marc N.
    Lee, Joshua D.
    CONTEMPORARY CLINICAL TRIALS, 2016, 49 : 57 - 64
  • [44] No Increase in Chronic Pain Among Opioid-Dependent Individuals Randomized to Treatment With Extended-Release Naltrexone Compared to Buprenorphine-Naloxone
    Tanum, Lars
    Latif, Zill-E-Huma
    Solli, Kristin
    Opheim, Arild
    Kunoe, Nikolaj
    Benth, Jurate
    Krajci, Peter
    BIOLOGICAL PSYCHIATRY, 2019, 85 (10) : S211 - S212
  • [45] Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Month Naturalistic Study
    Brenna, Ida Halvorsen
    Waleur, Karin Merethe
    Benth, Jurate Saltyte
    Solli, Kristin K.
    Mordal, Jon
    Loberg, Else-Marie
    Weimand, Bente
    Tanum, Lars
    EUROPEAN ADDICTION RESEARCH, 2025, 31 (01) : 1 - 12
  • [47] Transition to Extended-release Naltrexone: Heroin Versus Prescription Opioid Users
    Mannelli, Paolo
    Tompkins, D. Andrew
    Akerman, Sarah
    Yu, Miao
    Nangia, Narinder
    Graham, Christine
    Sullivan, Maria
    Kosten, Thomas
    Bisaga, Adam
    AMERICAN JOURNAL ON ADDICTIONS, 2018, 27 (04): : 323 - 324
  • [48] Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
    Blair, Hannah A.
    DRUGS & THERAPY PERSPECTIVES, 2024, 40 (02) : 61 - 71
  • [49] Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
    Hannah A. Blair
    Drugs & Therapy Perspectives, 2024, 40 : 61 - 71
  • [50] Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons With Opioid Use Disorder: A Case Series
    Hansen, Elizabeth Rose
    South, Anna Maria
    Lofwall, Michelle R.
    Fanucchi, Laura C.
    JOURNAL OF ADDICTION MEDICINE, 2024, 18 (01) : 65 - 67